Academic Alliances
GALLERY
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/cd7108c6164a17a66567c0e4737b86cabraininflammationotherprocessassociated260nw1736335886.jpg)
NeurANO Bioscience
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/165916e9efe6117cb884d00f4de31a0cbrainpuzzle260nw136775933.jpg)
NeurANO Bioscience
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/82ee1e87245569a78123e158003c6b32doctorpatientsufferingalzheimerdisease260nw1747746602.jpg)
NeurANO Bioscience
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/4b38c01d7bffd6a9ae1a9554049f75cbfemaledoctorexaminingbraincat260nw14906014.jpg)
NeurANO Bioscience
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/e7394e7ee8f217875dc773e61e6e15f7mrihumanbraintomographybackground260nw167475890.jpg)
NeurANO Bioscience
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/f9e1bfca6e1d42cb261c29e7292bee4a3drenderedillustrationnervecell260nw462373849.jpg)
NeurANO Bioscience
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/16329dcb79fac6c93f219b4e72396130backviewpatienteegequipment260nw1104373943.jpg)
NeurANO Bioscience
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/f271da837ec11e79232958a0ff7b2af0compositionhumanbrainmedicaldata260nw1989353075.jpg)
NeurANO Bioscience
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/e297d5dd18ca5f60433a1d3b1b3345f1femaledoctorbrainmedicalconcept260nw2089349557.jpg)
NeurANO Bioscience
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/ccac633243411812a156e5b4a4012b19youngfemaleelectrodeequipmenton260nw1104373931.jpg)
NeurANO Bioscience
News
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/36bff3a88e000e157157bb66fa3cd851BIO2022.png)
June 2022
NeurANO Bioscience was selected to present at the BIO2022 start-up stadium on June 14, 2022.
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/b01ab2f88509486cfd1143f6ae5c2011CLS.jpg)
May 2022
NeurANO Bioscience was selected for a competitive FAST Advisory program by the California LifeScience (CLS) organization.
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/f7328120ba4b7b8c098ac52566b53c51Aging.jpg)
September 2021
NeurANO Bioscience was awarded the SBIR Phase I grant “Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for treatment of opioid use disorder” from the National Institute on Aging.
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/6fc2a188ee41fc9e4219acc760aaf172Stroke.jpg)
August 2021
NeurANO Bioscience was awarded SBIR Phase I grant “Preclinical evaluation of a rationally designed nanotherapeutic for Huntington's disease” from the National Institute on Neurological disorders and stroke.
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/0b7ea872d9f156a308cc416a08e24304SFN2019.jpg)
October 2019
NeurANO Bioscience presented the Proof-of-Concept data for the project "Exclusive targeting of extrasynaptic NMDA receptors improves mice cognitive function after mild traumatic brain injury" ( https://www.abstractsonline.com/pp8/#!/7883/presentation/68229) and " Exclusive antagonists of extrasynaptic NMDA receptors for autism (https://www.abstractsonline.com/pp8/#!/7883/presentation/47176)
![](https://d1hz0qcu1muexe.cloudfront.net/upload/624404f069ae73000f7af51f/large/7dd1f41550c87f83bfb031cf22e3a031Drug.jpg)
August 2019
NeurANO Bioscience was awarded SBIR Phase I grant “Evaluation of the therapeutic potential of exclusive antagonists of extrasynaptic NMDA receptors for treatment of opioid use disorder” from the National Institute on Drug Abuse.